



Melanie Lee joins BTG plc Board as Non-Executive Director

Oxford, UK, 29 November 2010: Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, announces its Chief Executive Officer, Melanie Lee, has joined the Board of BTG plc (LSE:BGC) as a Non-Executive Director.

The BTG announcement follows:

BTG plc (LSE:BGC), the specialty pharmaceuticals company, today announces the appointment of Dr Melanie Lee CBE as a non-executive director of the Board, effective from today.

Melanie Lee is the Chief Executive Officer of Syntaxin Limited, a biotechnology company developing novel biopharmaceuticals to control cell secretion, and Founder and Director of the pharmaceutical consultancy Think10. She also chairs the board of Cancer Research Technology Limited, the cancer-focused technology development and commercialisation arm of Cancer Research UK. Melanie was formerly President of New Medicines and Executive VP R&D with UCB, having been R&D Director and a member of the board of the FTSE100 company Celltech plc before its merger with UCB.

Dr John Brown, BTG's chairman, commented: "Melanie brings a great deal of additional pharmaceutical industry experience to the Board, and we look forward to working with her as BTG continues to develop its business."

-ends-

Contact Details

Syntaxin Ltd
Melanie Lee, Nigel Clark
Tel: +44 (0)1235 552161
Email: Melanie.lee@syntaxin.com

Media

Capital MS&L
Mary Clark, Justine Lamond & Hollie Vile
Tel: +44 (0)20 7307 5337
Email: Syntaxin@capitalmsl.com

About Syntaxin (www.syntaxin.com)

Syntaxin discovers and develops a new class of biopharmaceuticals which treat disease through selective inhibition of cell secretory processes. It is developing cell secretion inhibitors for the treatment of a range of endocrine diseases, including acromegaly.

Syntaxin's new Executive Management, appointed in February 2010, brings a wealth of industry experience to the Company. Chief Executive Officer, Dr Melanie Lee, spent a decade in research with GlaxoSmithKline and subsequently held leadership positions at Celltech and UCB. Chief Business Officer, Dr Nigel Clark, was formerly Vice President Business Development with Vernalis and has a strong track record in building strategic alliances. Dr John Court, Chief Development Officer, was previously founder and CEO of Fulcrum

Pharma, an international contract drug development business, following R&D roles at Roche and Wellcome.

Syntaxin was founded in late 2005 through a spinout of intellectual property and scientists from the Health Protection Agency, and benefits from 15 years of research in the field of bacterial toxin engineering. The company owns dominant patents and know how in the design, manufacture and use of novel cell TSI based on engineered botulinum toxins. It has established a strong IP base with over 40 granted patents covering the platform and products. It is backed by a blue chip investor base including: Abingworth, Lundbeckfond Ventures, LSP, Ipsen, JJDC, Quest, Seventure, and SR One.

Syntaxin's Targeted Secretion Inhibitors (TSI) technology platform

Syntaxin's TSI products are biological molecules synthesized in microbial cell culture, which selectively bind to their chosen targeted cells and become internalised to deliver endopeptidases into the cell's cytoplasm, preventing further vesicular secretion. A single dose provides an extended duration of action from weeks to months.